Mbx Biosciences, INC. (MBX) — SEC Filings

Overview

Mbx Biosciences, INC. (MBX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 22, 2026: MBX Biosciences, Inc. filed its Annual Report to Security Holders (ARS) on April 22, 2026, for the period ending December 31, 2025. The filing includes the complete submission text file and a PDF document detailing the company's year-end financial information. MBX Biosciences, Inc. is located in Car

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 2 bearish, 27 neutral, 2 mixed. The dominant filing sentiment for Mbx Biosciences, INC. is neutral.

Filing Type Overview

Mbx Biosciences, INC. (MBX) has filed 1 144, 1 ARS, 1 DEFA14A, 2 4/A, 4 10-Q, 9 8-K, 1 DEF 14A, 1 10-K, 4 SC 13G, 4 SC 13D, 2 S-1/A, 1 S-1 with the SEC between Aug 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (31)

• MBX Biosciences Files 2025 Annual Report — ARS · Apr 22, 2026 Risk: low
  MBX Biosciences, Inc. filed its Annual Report to Security Holders (ARS) on April 22, 2026, for the period ending December 31, 2025. The filing includes the comp
• MBX Biosciences Files Proxy Materials — DEFA14A · Apr 22, 2026 Risk: low
  MBX Biosciences, Inc. filed a DEFA14A on April 22, 2026, related to additional definitive proxy soliciting materials. The filing includes the main DEFA14A docum
• MBX Biosciences Files Ownership Amendment — 4/A · Apr 22, 2026 Risk: low
  MBX Biosciences, Inc. filed an amendment (4/A) on April 22, 2026, to a previous statement of changes in beneficial ownership of securities, with the period of r
• MBX Biosciences Files 4/A Amendment — 4/A · Apr 22, 2026 Risk: low
  This 4/A filing amends a previous statement of changes in beneficial ownership for MBX Biosciences, Inc. The amendment was filed on April 22, 2026, and pertains
• MBX Biosciences Insider Richard Bartram Files Proposed Stock Sale — 144 · Mar 25, 2026
  This 144 filing indicates that Richard Bartram, associated with MBX Biosciences, Inc., is proposing to sell securities. While the specific number of shares or d
• MBX Biosciences Boosts Cash by $173.8M, Losses Mount Amid R&D Push — 10-Q · Nov 6, 2025 Risk: high
  MBX Biosciences, Inc. (MBX) reported a significant increase in its cash and cash equivalents, reaching $223.1 million as of September 30, 2025, up from $49.3 mi
• MBX Biosciences Enters Material Definitive Agreement — 8-K · Sep 26, 2025 Risk: medium
  MBX Biosciences, Inc. entered into a Material Definitive Agreement on September 24, 2025. The filing also includes financial statements and exhibits related to
• MBX Biosciences Files 8-K Report — 8-K · Sep 22, 2025 Risk: low
  On September 22, 2025, MBX Biosciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events. No specific
• MBX Biosciences Files 8-K — 8-K · Sep 4, 2025 Risk: low
  MBX Biosciences, Inc. filed an 8-K on September 4, 2025, reporting on other events and financial statements. The company, incorporated in Delaware, is based in
• MBX Biosciences' Q2 Loss Widens Amid R&D Push — 10-Q · Aug 7, 2025 Risk: high
  MBX Biosciences, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company posted a net l
• MBX Biosciences Files 8-K — 8-K · Jun 16, 2025 Risk: low
  MBX Biosciences, Inc. filed an 8-K on June 16, 2025, to report on other events and financial statements. The filing does not contain specific details about new
• 8-K Filing — 8-K · Jun 9, 2025
• MBX Biosciences: Director Departs, New Officers Elected — 8-K · Jun 6, 2025 Risk: medium
  MBX Biosciences, Inc. announced on June 5, 2025, the departure of Director David E. Johnson. The company also reported on the election of new directors and the
• MBX Biosciences Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: medium
  MBX Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business operations. Key events an
• MBX Biosciences Files 2024 Proxy Statement — DEF 14A · Apr 23, 2025 Risk: low
  MBX Biosciences, Inc. filed its definitive proxy statement (DEF 14A) on April 23, 2025, for the fiscal year ending December 31, 2024. The filing, which does not
• MBX Biosciences Reports Director Departure, Officer Compensation — 8-K · Apr 7, 2025 Risk: low
  MBX Biosciences, Inc. announced on April 7, 2025, the departure of Director David E. Johnson. The company also reported on compensatory arrangements for its off
• 10-K Filing — 10-K · Mar 17, 2025
• MBX Biosciences Acquired by Aptalis Pharma for $100M — 8-K · Jan 7, 2025 Risk: medium
  MBX Biosciences, Inc. announced on January 7, 2025, that it has entered into a definitive agreement to be acquired by Aptalis Pharma US, Inc. The transaction is
• SC 13G Filing — SC 13G · Nov 8, 2024
• MBX Biosciences Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  MBX Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position, including common stock and prefer
• SC 13G Filing — SC 13G · Nov 1, 2024
• Frazier Life Sciences Takes 10.4% Stake in MBX Biosciences — SC 13D · Sep 23, 2024 Risk: medium
  On September 23, 2024, Frazier Life Sciences Public Fund, L.P. and its affiliates, including Albert Cha and Daniel Estes, reported a beneficial ownership of 1,7
• SC 13G Filing — SC 13G · Sep 23, 2024
• Norwest Venture Partners Discloses Stake in MBX Biosciences — SC 13D · Sep 23, 2024 Risk: medium
  On September 23, 2024, Norwest Venture Partners XVI, LP, along with Genesis VC Partners XVI, LLC, NVP Associates, LLC, Jeffrey Crowe, and Tiba Aynechi, filed a
• NEA 17 Files SC 13D for MBX Biosciences — SC 13D · Sep 23, 2024 Risk: medium
  New Enterprise Associates 17, L.P. (NEA 17) and its group members, including individuals like Ali Behbahani and Scott D. Sandell, have filed a Schedule 13D on S
• OrbiMed Adjusts Stake in MBX Biosciences — SC 13D · Sep 23, 2024 Risk: medium
  On September 16, 2024, OrbiMed Advisors LLC, along with its affiliates OrbiMed Capital GP VII LLC and OrbiMed Genesis GP LLC, reported a change in beneficial ow
• SC 13G Filing — SC 13G · Sep 20, 2024
• MBX Biosciences Files 8-K for Bylaws and Financials — 8-K · Sep 16, 2024 Risk: low
  MBX Biosciences, Inc. filed an 8-K on September 16, 2024, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements and ex
• MBX Biosciences Files IPO Amendment — S-1/A · Sep 9, 2024 Risk: medium
  MBX Biosciences, Inc. filed an S-1/A amendment on September 9, 2024, for its initial public offering. The company, incorporated in Delaware, is seeking to regis
• MBX Biosciences Files IPO Amendment — S-1/A · Aug 30, 2024 Risk: medium
  MBX Biosciences, Inc. filed an S-1/A amendment on August 30, 2024, for its initial public offering. The company, incorporated in Delaware, is seeking to registe
• MBX Biosciences Files S-1 for Public Offering — S-1 · Aug 23, 2024 Risk: medium
  MBX Biosciences, Inc., a Delaware-based pharmaceutical company, filed an S-1 registration statement on August 23, 2024, to register its securities for public of

Risk Profile

Risk Assessment: Of MBX's 24 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Mbx Biosciences, INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: N/A
• Net Income: -$21,618,000
• EPS: -$0.63
• Debt-to-Equity: 0.03
• Cash Position: $223,125,000
• Operating Margin: N/A
• Total Assets: $400,076,000
• Total Debt: $12,538,000

Key Executives

• Steven L. Hoerter
• David E. Johnson
• Albert Cha
• Daniel Estes
• Jeffrey Crowe
• Tiba Aynechi
• Matthew De Dominicis
• Ali Behbahani
• Scott D. Sandell
• P. Kent Hawryluk

Industry Context

MBX Biosciences operates in the highly competitive and capital-intensive biopharmaceutical industry. Success hinges on the discovery, development, and regulatory approval of novel therapeutics. The industry is characterized by long development cycles, significant R&D investment, and the potential for substantial returns upon successful commercialization, but also high failure rates and intense competition from established pharmaceutical giants and emerging biotech firms.

Top Tags

sec-filing (5) · financials (4) · ownership-change (4) · amendment (3) · ipo (3) · pharmaceuticals (2) · Biotechnology (2) · Net Loss (2) · R&D Expenses (2) · filing (2)

Key Numbers

• Filing Date: 2026-04-22 — Date the amendment was accepted
• Period of Report: 2025-11-06 — Date to which the ownership changes relate
• Cash and cash equivalents: $223.1M — Increased from $49.3M at Dec 31, 2024, due to public offering
• Gross proceeds from September 2025 public offering: $199.9M — Generated from 11,108,055 shares of common stock
• Net loss for nine months ended September 30, 2025: $64.9M — Increased from $46.3M in the prior year period
• Accumulated deficit: $202.4M — As of September 30, 2025, indicating significant historical losses
• Total cash, cash equivalents and marketable securities: $391.7M — Management believes this is sufficient for at least 12 months
• Research and development expenses: $19.3M — For the three months ended September 30, 2025, up from $16.7M in 2024
• Common shares outstanding: 44,902,302 — As of November 3, 2025, reflecting dilution from public offering
• Commission File Number: 001-42272 — Identifies the company's SEC filing history.
• IRS Employer Identification No.: 84-1882872 — Tax identification number for the company.
• Revenue: $0 — No revenue reported for Q2 2025 or YTD 2025, indicating pre-commercial stage.
• Net Loss (Q2 2025): $15.2M — Increased from $13.5M in Q2 2024, showing widening losses.
• Net Loss (YTD 2025): $30.1M — Increased from $26.5M in YTD 2024, reflecting higher operating expenses.
• R&D Expenses (Q2 2025): $12.1M — Up from $10.8M in Q2 2024, indicating continued investment in drug development.

Related Companies

DCPH · MBXB

Frequently Asked Questions